Novo Nordisk shares pop 10% on early-stage weight loss drug trial results
1. Novo Nordisk reports positive early-stage obesity drug results. 2. Average weight reduction of 22% in patients after 36 weeks. 3. Shares increased by 9.5% due to the trial announcement.